Converge Bio
Claymont, US · Founded 2024 · Delaware corporation · 53 employees on LinkedIn · 4 known investors
Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.
Founders & leadership
Converge Bio was founded in 2024 by Dov Gertz.
Board
ST
AH
Investors · 4
Reported raises · per SEC filings
Form D private placements$25M disclosed across 1 round · 2025
▶$25MraisedApr 2026 · 19 investors · BiotechnologyRule 506(b)
▶$25MraisedApr 2026 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shahar TzafrirDirector
- Dov GertzExecutive Officer, Director
- Oded KalevExecutive Officer, Director
- Andrew HedinDirector
- Iddo WeinerExecutive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Bridgebio19 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Transition Bio18 shared keywordsTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Generate Biomedicines17 shared keywordsGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Engage Bio17 shared keywordsEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Formation Bio16 shared keywordsFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
Maven Bio15 shared keywordsMaven Bio provides software for biotech investment firms to accelerate due diligence and thesis development, automating screening, competitive analysis, and clinical data review to compress research timelines from days to hours.
Form Bio13 shared keywordsForm Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
AskBio12 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Companies competing with Converge Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Converge Bio do?
- Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.
- Who founded Converge Bio?
- Converge Bio was founded by Dov Gertz in 2024.
- Who are Converge Bio's investors?
- Converge Bio's investors include Bessemer Venture Partners, TLV Partners, SARAS CAPITAL, Vintage Investment Partners.
- How much funding has Converge Bio raised?
- Converge Bio has disclosed $25M raised across 1 round.
- Where is Converge Bio headquartered?
- Converge Bio is headquartered in Claymont, US.